Tags :GastroPlus

GastroPlus 10.2: Physiologically Based PBPK/PBBM Modeling Software GastroPlus 10.2 (GPX.2) is Simulations Plus’ latest major release of the physiologically based pharmacokinetic (PBPK) modeling software. Described as “the largest upgrade ever,” this version introduces the ACATPlus GI model, AI-powered tools, and significant automation enhancements . Key New Features in Version 10.2 ACATPlus Advanced GI Model Expanded Compartments: Extended from classic ACAT model to 13 compartments with new colon sub-divisions (ascending, transverse, descending, sigmoid, rectum) and detailed tissue layers (mucus, mucosa, submucosa, muscle) Microbiome Metabolism: Simulates compound transformation by gut microbiota Local Tissue Concentrations: Predicts drug levels in intestinal tissues, critical for locally acting drugs New Dosing Routes Intramuscular (IM) & Subcutaneous (SubQ) Models: Simulate long-acting injectable formulations; accounts for particle size,...

  Overview of GastroPlus 10.1 GastroPlus is a leading mechanistically based simulation software developed by Simulations Plus, Inc., designed for physiologically-based pharmacokinetics (PBPK) and physiologically-based biopharmaceutics modeling (PBBM). It enables researchers, pharmaceutical scientists, and drug developers to predict drug absorption, distribution, metabolism, excretion (ADME), and pharmacodynamics across various routes of administration (e.g., oral, intravenous, dermal, inhalation) in humans and animals. Version 10.1 is part of the established GastroPlus lineup, focusing on accurate in silico predictions to optimize drug formulation, reduce animal testing, and accelerate R&D workflows. Key Features of GastroPlus 10.1 Core Modeling Capabilities: Simulates gastrointestinal (GI) absorption using the Advanced Compartmental Absorption and Transit (ACAT™) model, which accounts for factors like dissolution, precipitation, metabolism, and transport in GI compartments....

GastroPlus is one of the most widely used PBPK/PD and formulation simulation software in the world, which is widely used by FDA, EMA, China NMPA, Japan Ministry of Health and Welfare, and major pharmaceutical companies: Regulatory departments verify the data reasonableness of new drugs and generic drugs, assess the risk of medication, etc; Pharmaceutical companies examine the process of drug absorption and disposal in vivo, make decisions on the formulation development of new drugs and generics, and guide the conduct of clinical trials; Academic units conduct mechanism research, guide experimental design, and reduce blind groping. GastroPlus 9.5